glp-1 drug companies Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Expert Guide to GLP-1 Telehealth

10.1111/j.1478-3231.2006.01315.x 57

This enhanced effectiveness is related to the medicines'capacity to influence both peripheral and central pathways that govern energy balance

In a later study of small numbers of rats studied for 10 weeks, exenatide increased inflammatory cell infiltrate with interstitial edema and fibrosis in 5 of 15 rats (122)

In any case, the shift towards oral drugs provides a significant demand tailwind for CDMOs, given the much higher API requirements (due to lower bioavailability)

Weight changes during the first month at a starting dose are variable

Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis